189 related articles for article (PubMed ID: 27129144)
21. Analysis of ecstasy tablets using capillary electrophoresis with capacitively coupled contactless conductivity detection.
Porto SK; Nogueira T; Blanes L; Doble P; Sabino BD; do Lago CL; Angnes L
J Forensic Sci; 2014 Nov; 59(6):1622-6. PubMed ID: 25039689
[TBL] [Abstract][Full Text] [Related]
22. Impact of a transient instability of the ecstasy market on health concerns and drug use patterns in The Netherlands.
Brunt TM; Niesink RJ; van den Brink W
Int J Drug Policy; 2012 Mar; 23(2):134-40. PubMed ID: 21741814
[TBL] [Abstract][Full Text] [Related]
23. The content of ecstasy tablets: implications for the study of their long-term effects.
Cole JC; Bailey M; Sumnall HR; Wagstaff GF; King LA
Addiction; 2002 Dec; 97(12):1531-6. PubMed ID: 12472637
[TBL] [Abstract][Full Text] [Related]
24. Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 - A potential risk to users?
Couchman L; Frinculescu A; Sobreira C; Shine T; Ramsey J; Hecht M; Kipper K; Holt D; Johnston A
Drug Test Anal; 2019 Aug; 11(8):1172-1182. PubMed ID: 31009168
[TBL] [Abstract][Full Text] [Related]
25. Quantitative determination of 3,4-methylenedioxymethamphetamine by thin-layer chromatography in ecstasy illicit pills in Tehran.
Shetab Boushehri SV; Tamimi M; Kebriaeezadeh A
Toxicol Mech Methods; 2009 Nov; 19(9):565-9. PubMed ID: 20047512
[TBL] [Abstract][Full Text] [Related]
26. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users.
Brunt TM; Koeter MW; Niesink RJ; van den Brink W
Psychopharmacology (Berl); 2012 Apr; 220(4):751-62. PubMed ID: 21993879
[TBL] [Abstract][Full Text] [Related]
27. There's something about Molly: The underresearched yet popular powder form of ecstasy in the United States.
Palamar JJ
Subst Abus; 2017; 38(1):15-17. PubMed ID: 27925866
[TBL] [Abstract][Full Text] [Related]
28. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
[TBL] [Abstract][Full Text] [Related]
29. Results of an international drug testing service for cryptomarket users.
Caudevilla F; Ventura M; Fornís I; Barratt MJ; Vidal C; Lladanosa CG; Quintana P; Muñoz A; Calzada N
Int J Drug Policy; 2016 Sep; 35():38-41. PubMed ID: 27239011
[TBL] [Abstract][Full Text] [Related]
30. From ecstasy to MDMA: Recreational drug use, symbolic boundaries, and drug trends.
Edland-Gryt M; Sandberg S; Pedersen W
Int J Drug Policy; 2017 Dec; 50():1-8. PubMed ID: 28869878
[TBL] [Abstract][Full Text] [Related]
31. The Texture of Psychoactive Illicit Drugs in Iran: Adulteration with Lead and other Active Pharmaceutical Ingredients.
Akhgari M; Moradi F; Ziarati P
J Psychoactive Drugs; 2018; 50(5):451-459. PubMed ID: 30130472
[TBL] [Abstract][Full Text] [Related]
32. Solid-phase extraction for profiling of ecstasy tablets.
Rashed AM; Anderson RA; King LA
J Forensic Sci; 2000 Mar; 45(2):413-7. PubMed ID: 10782963
[TBL] [Abstract][Full Text] [Related]
33. Impurity profiling of seized MDMA tablets by capillary gas chromatography.
Palhol F; Boyer S; Naulet N; Chabrillat M
Anal Bioanal Chem; 2002 Sep; 374(2):274-81. PubMed ID: 12324849
[TBL] [Abstract][Full Text] [Related]
34. Qualitative transformations of street-seized ecstasy over a decade: A case study in Rio de Janeiro (Brazil).
Antonio ADS; Wurzler GT; Bhering CA; de Oliveira AS; Cohen LSDA; de Oliveira MAM; de Aquino Neto FR; Vanini G
J Forensic Sci; 2024 Jul; 69(4):1198-1211. PubMed ID: 38691107
[TBL] [Abstract][Full Text] [Related]
35. Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry.
Cheng JY; Chan MF; Chan TW; Hung MY
Forensic Sci Int; 2006 Oct; 162(1-3):87-94. PubMed ID: 16860955
[TBL] [Abstract][Full Text] [Related]
36. Putting an Ecstasy test kit to the test: harm reduction or harm induction?
Murray RA; Doering PL; Boothby LA; Merves ML; McCusker RR; Chronister CW; Goldberger BA
Pharmacotherapy; 2003 Oct; 23(10):1238-44. PubMed ID: 14594341
[TBL] [Abstract][Full Text] [Related]
37. Organic impurity profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in The Netherlands.
van Deursen MM; Lock ER; Poortman-van der Meere AJ
Sci Justice; 2006; 46(3):135-52. PubMed ID: 17388242
[TBL] [Abstract][Full Text] [Related]
38. Optimization of HS-SPME/GC-MS analysis and its use in the profiling of illicit ecstasy tablets (Part 1).
Bonadio F; Margot P; Delémont O; Esseiva P
Forensic Sci Int; 2009 May; 187(1-3):73-80. PubMed ID: 19356870
[TBL] [Abstract][Full Text] [Related]
39. 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market.
Giroud C; Augsburger M; Rivier L; Mangin P; Sadeghipour F; Varesio E; Veuthey JL; Kamalaprija P
J Anal Toxicol; 1998 Sep; 22(5):345-54. PubMed ID: 9737327
[TBL] [Abstract][Full Text] [Related]
40. Shifts in Unintentional Exposure to Drugs Among People Who Use Ecstasy in the Electronic Dance Music Scene, 2016-2019.
Palamar JJ; Salomone A
Am J Addict; 2021 Jan; 30(1):49-54. PubMed ID: 32813326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
